The Oxford/AstraZeneca vaccine does not appear to offer protection against mild and moderate cases of the South African variant of the CCP virus, a new study has found. In both the human trials and tests on the blood of those vaccinated, the vaccine “did not show protection against mild-moderate COVID-19” caused by the 501Y.V2 variant, the dominant CCP (Chinese Communist Party) virus strain in South Africa, said the study, which was first reported by the Financial Times. The jab’s efficacy against severe disease caused by the variant, hospitalisations, and deaths has not yet been determined, according to the study, which was led by South Africa’s University of the Witwatersrand and Oxford University. The randomised, double-blind study enrolled 2,026 HIV-negative individuals, with a median age of 31. Half the group was given at least one dose of placebo, with the other half receiving at least one dose of the Oxford vaccine. …